Drug

XERMELO®

telotristat ethyl

Xermelo Overview

This is a summary of the European public assessment report (EPAR) for Xermelo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Xermelo.

For practical information about using Xermelo, patients should read the package leaflet or contact their doctor or pharmacist.

Xermelo can only be obtained with a prescription. It is available as tablets containing 250 mg of telotristat and the recommended dose is one tablet three times a day. Doses may need to be reduced in patients with mildly or moderately reduced liver function. Doctors may consider stopping treatment if patients do not benefit after 12 weeks. For further information, see the package leaflet.

The active substance in Xermelo, telotristat, blocks the action of enzymes called L-tryptophan hydroxylases. These enzymes are needed for the production of serotonin. By blocking the enzymes, telotristat reduces the production of serotonin in patients with carcinoid syndrome, and so relieves the symptoms of the condition.

The benefits of adding Xermelo to treatment have been shown in one main study involving 135 patients with carcinoid syndrome whose diarrhoea had not been fully controlled with somatostatin analogues alone. Xermelo was compared with placebo (a dummy treatment) and the main measure of effectiveness was the change in average number of daily bowel movements over the 12 weeks of the study.

At the start, patients given Xermelo had an average of 6.1 bowel movements per day, and this went down over the 12 weeks to an average of 4.7 per day, a reduction of 1.4 movements. Patients taking placebo were having an average of 5.2 bowel movements daily at the start, which fell to an average of 4.6 movements daily, a fall of 0.6 movements. The effects of Xermelo were seen from about 3 weeks after starting treatment.

Xermelo has been shown to produce a reduction in the number of bowel movements suffered by patients with carcinoid syndrome not fully controlled with other medicines. Although small, this reduction was considered significant given that patients view the frequency of bowel movements as a symptom with an important impact on their quality of life. The side effects that were seen, which mainly affected the gut, did not raise major concerns and were considered mild and manageable. The European Medicines Agency therefore decided that Xermelo’s benefits are greater than its risks and recommended that it be approved for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xermelo have been included in the summary of product characteristics and the package leaflet.

The European Commission granted a marketing authorisation valid throughout the European Union for Xermelo on 18 September 2017.

For more information about treatment with Xermelo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

What are the risks associated with Xermelo?

The most common side effects with Xermelo (which may affect more than 1 in 10 people) are abdominal (belly) pain, increases in the liver enzyme gamma-glutamyl transferase, and tiredness, and are usually mild or moderate. The commonest side effect severe enough to cause treatment to be stopped is abdominal pain.

Owner of copyright and other intellectual property rights to European Medicines Agency

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Find more drugs

CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR)

Cancer.cankado

At one place know the best information on various cancer drugs and common symptoms associated.

CANKADO’s PRO-react Onco helps efficient patient physician communication in the treatment phase.

© 2020 Cancer.Cankado. All rights Reserved

CANKADO is approved as an active Class I medical device within the European Union (registration number DE/CA59/11976/2017) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B.

Auto Translate »

This website uses cookies to provide their services and to analyze traffic. By using this website, you agree to use cookies.